{
  "id": 3328810,
  "title": "Computational Pathology and Spatial Microdosimetry Guide Radiopharmaceutical Selection for TROP2-Targeted Alpha versus Beta Radionuclide Drug Conjugates (RDCs)",
  "url": "https://urgent.news/2026/08/25/computational-pathology-and-spatial-microdosimetry-guide",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-25T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.19.745876v1?rss=1"
  },
  "original_language": "en",
  "account": "Trophoblast cell surface antigen 2 (TROP2) is a protein found on the surface of certain aggressive epithelial cancers. Some treatments for these cancers involve attaching radioactive substances to drugs that target TROP2, but resistance to these treatments and undesirable side effects can still occur. Radionuclide drug conjugates (RDCs) are a promising alternative, as they allow for radiation to be delivered directly to the cancer cells.\n\nThe study compared two types of radioactive substances - beta emitters like 177Lu, which have a longer range but lower energy, and alpha emitters like 225Ac, which have a shorter range but higher energy. To determine which would be more effective, the researchers used a computational pipeline to analyze the microscopic distribution of TROP2 protein in tissue samples. This allowed them to model the radiation dose distribution to the cancer cells in a spatially accurate way.\n\nThe results showed that TROP2 expression was clustered and focal in the tumors, with only a small fraction of cells actually expressing the protein. When the RDCs labeled with 225Ac were used, they were found to be more effective at delivering the radiation to the cancer cells compared to the 177Lu-labeled RDCs. In fact, 225Ac-labeled RDCs led to a significantly higher therapeutic index, meaning they were much better at targeting the cancer cells while sparing the surrounding healthy tissue. This suggests that using alpha-emitting isotopes like 225Ac could be a more effective strategy for treating cancers with TROP2 overexpression.",
  "summary": "Background: Trophoblast cell surface antigen 2 (TROP2, encoded by TACSTD2) is a transmembrane glycoprotein overexpressed in multiple aggressive epithelial carcinomas. While antibody drug conjugates targeting TROP2 have achieved regulatory approvals, acquired payload resistance and systemic off-target toxicities limit sustained remissions. Radionuclide Drug Conjugates (RDCs) represent a potent…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}